Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it works.
The Man in Room 117
Andrey Shevelyov would rather live on the street than take antipsychotic medication. Should it be his decision to make?
Buried in Wegovy Costs, North Carolina Will Stop Paying for Obesity Drugs
Starting April 1, state employees in North Carolina will no longer have insurance coverage for costly weight-loss medications like Wegovy and Zepbound.
6 Paperbacks to Read This Week
Recommended reading from the Book Review, including titles by Geraldine Brooks, Jefferson Cowie, Parini Shroff and more.
Six Reasons Drug Prices Are So High in the U.S.
Research shows prices in the United States are nearly double those in other well-off countries.
El caso de Singulair, un medicamento para el asma que provocó angustia
Un medicamento contra el asma, que ya se consigue como genérico, todavía es usado por millones de personas en EE. UU., incluso después de que miles de pacientes y decenas de estudios han descrito sus riesgos.
Un esperanzador experimento de ultrasonido para los tratamientos del cerebro
Algunos fármacos para tratar enfermedades como el alzhéimer o el cáncer se enfrentan a un obstáculo: la barrera hematoencefálica. Un ensayo en fases iniciales pretende resolver esa limitación.
Federal Scientists Recommend Easing Restrictions on Marijuana
In newly disclosed documents, federal researchers find that cannabis may have medical uses and is less likely to cause harm than drugs like heroin.
The Billionaires Spending a Fortune to Lure Scientists Away From Universities
Arena BioWorks is promising big paydays to nearly 100 researchers from Harvard, M.I.T. and other prestigious institutions.
Why Casey Left Substack, Elon Musk and Drugs, and an A.I. Antibiotic Discovery
It’s a drug episode.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.